A first-ever human clinical trial on cannabigerol (CBG), a lesser-known cannabinoid, found it significantly improves memory and reduces anxiety and stress without causing intoxication or impairment. Conducted by researchers at Washington State University (WSU) and UCLA and published in *Scientific Reports*, the study involved 34 participants taking either 20mg of CBG or a placebo. Those who took CBG reported a 26.5% reduction in anxiety and improved verbal memory compared to the placebo group.
Lead author Carrie Cuttler noted that the memory enhancement was unexpected and plans to replicate the study for further validation. The study suggests CBG may be a promising treatment for anxiety and stress, with potential effects linked to its anxiety-reducing properties. Cuttler emphasizes that while these findings are promising, more research is needed to fully understand CBG’s benefits and safety.
The study was informed by earlier survey data showing that a majority of CBG users found it more effective for anxiety relief than conventional medications. Given the growing interest in CBG, the research offers some of the first evidence to support claims of its therapeutic potential. Follow-up studies are planned to explore CBG’s effects on physiological markers and potential benefits for other conditions like menopause.